Efficacy of Traditional Chinese Medicine Treatment Alone for Recurrent and Refractory Castration-Resistant Prostate Cancer: A Case Report and Literature Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of Traditional Chinese Medicine Treatment Alone for Recurrent and Refractory Castration-Resistant Prostate Cancer: A Case Report and Literature Review

Published:2024 Issue:06 Volume:14 Page:1310-1315
ISSN:2161-8712
Container-title:Advances in Clinical Medicine
language:
Short-container-title:ACM

Author:

杨琴

Publisher

Hans Publishers

Reference18 articles.

1. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis

2. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches

3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

4. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

5. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3